Boehringer and Click Therapeutics Reveal Promising Phase III Results for Schizophrenia Treatment

2025-10-14 digitalcare

Amsterdam, Tuesday, 14 October 2025.
CT-155, a digital therapeutic for schizophrenia, shows significant improvement in negative symptoms, with a 6.8-point betterment compared to the control group, demonstrating its potential impact on mental health care.

A New Frontier in Digital Therapeutics

Boehringer Ingelheim and Click Therapeutics recently revealed promising results from the Phase III CONVOKE study on CT-155 at the 38th Annual European College of Neuropsychopharmacology Congress in Amsterdam. This investigational prescription digital therapeutic (PDT) targets negative symptoms of schizophrenia, which include diminished emotional expression and lack of motivation. The study involved 464 adult patients who were already stabilized for positive symptoms but continued to experience negative symptoms [1][2].

Significant Clinical Improvement

CT-155 demonstrated a 6.8-point improvement on the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP), compared to a 4.2-point improvement in the control group, establishing statistical significance. This improvement highlights the potential of CT-155 to fill a critical gap in mental health care, as traditional antipsychotic treatments often leave negative symptoms unaddressed [2][3].

High Engagement and Safety Profile

Throughout the 16-week study, participant engagement remained high, with over 70% of subjects utilizing the CT-155 app consistently until week 15. The therapeutic also showcased a favorable safety profile, reporting no serious adverse effects or trial discontinuations. These findings underscore the viability of digital therapeutics as a safe and engaging adjunct to conventional treatments [3][4].

Addressing Unmet Needs in Schizophrenia

Negative symptoms in schizophrenia often remain untreated, with approximately 50% of patients lacking adequate therapeutic options. The introduction of CT-155 aims to address these unmet needs by providing a scalable and accessible intervention. Having received FDA breakthrough device designation in January 2024, CT-155 was developed with direct input from patient groups, ensuring it meets real-life challenges faced by individuals with schizophrenia [2][3][5].

Bronnen

digital therapeutics schizophrenia